
X4 Pharmaceuticals, Inc.: updates and filings
Price
$2.96
November 19, 2026Market cap $302M
What Ploutos Investor adds for X4 Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Other material eventsForm8-K
- Oct 8, 2026Material agreement entered, material agreement ended, new material financial obligation, unregistered sale of shares, Regulation FD disclosureForm8-K
- Oct 7, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 21, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Sep 9, 2026Other material eventsForm8-K
- Sep 8, 2026Other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 1, 2026Officer or director change, Regulation FD disclosureForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026FilingFormEFFECT
- May 13, 2026Officer or director change, shareholder vote (amendment)Form8-K/A
- May 12, 2026Officer or director change, shareholder voteForm8-K
- May 12, 2026Correspondence with the SECFormCORRESP
- May 11, 2026Letter from the SECFormUPLOAD
- May 6, 2026Shelf registration for future offeringsFormS-3
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Mar 20, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 20, 2026Additional annual meeting materialFormDEFA14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Other material events | Document |
| Oct 8, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation, unregistered sale of shares, Regulation FD disclosure | Document |
| Oct 7, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 21, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Sep 9, 2026 | 8-K | Other material events | Document |
| Sep 8, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 1, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | EFFECT | Filing | Document |
| May 13, 2026 | 8-K/A | Officer or director change, shareholder vote (amendment) | Document |
| May 12, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 12, 2026 | CORRESP | Correspondence with the SEC | Document |
| May 11, 2026 | UPLOAD | Letter from the SEC | Document |
| May 6, 2026 | S-3 | Shelf registration for future offerings | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Mar 20, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 20, 2026 | DEFA14A | Additional annual meeting material | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 24, 2010.
The full analysis
What do X4 Pharmaceuticals's filings show?
The filings are where every one of X4 Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.